Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Regeneron Pharmaceuticals (REGN)

544.1   -4.1 (-0.75%) 01-27 03:02
Open: 558.91 Pre. Close: 548.2
High: 556.95 Low: 542.14
Volume: 901,677 Market Cap: 58,059M
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 559.564 - 562.512 562.512 - 565.019
Low: 535.201 - 538.52 538.52 - 541.343
Close: 538.675 - 544.282 544.282 - 549.051

Technical analysis

as of: 2021-01-26 4:48:14 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 652.81     One year: 762.48
Support: Support1: 502.11    Support2: 467.00
Resistance: Resistance1: 558.91    Resistance2: 652.81
Pivot: 515.44
Moving Average: MA(5): 541.57     MA(20): 507.15
MA(100): 541.20     MA(250): 543.56
MACD: MACD(12,26): 11.44     Signal(9): 5.40
Stochastic oscillator: %K(14,3): 88.31     %D(3): 90.05
RSI: RSI(14): 67.01
52-week: High: 664.64  Low: 328.13  Change(%): 60.4
Average Vol(K): 3-Month: 94558  10-Days: 92831

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
REGN has closed below upper band by 20.2%. Bollinger Bands are 62% wider than normal. The large width of the bands suggest high volatility as compared to REGN's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue.

Headline News

Tue, 26 Jan 2021
Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study - MarketWatch

Tue, 26 Jan 2021
Regeneron (REGN) Covid-19 Cocktail Shows Promise as 'Passive Vaccine' in Trial - Bloomberg

Mon, 25 Jan 2021
Regeneron Pharmaceuticals Inc. (REGN) Rises 1.94% for January 25 -

Mon, 25 Jan 2021
Why Now Could Be a Good Time to Buy Regeneron Stock - Barron's

Wed, 20 Jan 2021
Investing in Regeneron Pharmaceuticals (NASDAQ: REGN) Stocks -

Tue, 19 Jan 2021
Regeneron Pharmaceuticals Inc. (REGN) Rises 3.08% for January 19 -

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 105
Shares Float (M) 101
% Held by Insiders 2.90
% Held by Institutions 92.17
Shares Short (K) 1,960
Shares Short P. Month (K) 2,010

Stock Financials

EPS 27.290
EPS Est This Year 14.940
EPS Est Next Year 16.370
Book Value (p.s.) 96.010
Profit Margin 34.14
Operating Margin 33.76
Return on Assets (ttm) 13.0
Return on Equity (ttm) 30.6
Qtrly Rev. Growth 31.6
Gross Profit (p.s.) 38.528
Sales Per Share 88.117
EBITDA (p.s.) 31.947
Qtrly Earnings Growth 25.80
Operating Cash Flow (M) 2,170
Levered Free Cash Flow (M) 734

Stock Valuations

PE Ratio 19.94
PEG Ratio 0.94
Price to Book value 5.67
Price to Sales 6.17
Price to Cash Flow 26.29

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.